Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADOCY OTCMKTS:BPMUF NASDAQ:OCS NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADOCYAdocia$11.80$11.80$9.80▼$11.80$215.70M-0.12N/AN/ABPMUFBasilea Pharmaceutica$61.34$54.29$47.50▼$61.34$807.83M0.290 shsN/AOCSOculis$17.86-0.2%$18.92$10.79▼$23.08$781.12M0.2945,331 shs6,011 shsQUREuniQure$14.42+3.3%$14.66$4.45▼$19.18$764.67M0.081.44 million shs912,323 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADOCYAdocia0.00%0.00%0.00%0.00%0.00%BPMUFBasilea Pharmaceutica0.00%0.00%+6.31%+20.27%+27.39%OCSOculis-1.49%-4.02%-5.94%-0.72%+53.69%QUREuniQure-4.05%-3.32%-9.00%+48.67%+53.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADOCYAdociaN/AN/AN/AN/AN/AN/AN/AN/ABPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/AOCSOculis2.0627 of 5 stars3.53.00.00.02.00.00.6QUREuniQure2.6968 of 5 stars3.51.00.00.03.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADOCYAdocia 0.00N/AN/AN/ABPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/AOCSOculis 3.00Buy$35.3397.84% UpsideQUREuniQure 2.91Moderate Buy$37.82162.26% UpsideCurrent Analyst Ratings BreakdownLatest ADOCY, OCS, BPMUF, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/12/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/6/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADOCYAdocia$13.12M16.44N/AN/A($0.21) per share-56.19BPMUFBasilea Pharmaceutica$236.92M3.41$6.85 per share8.96$6.99 per share8.78OCSOculis$780K999.70N/AN/A$1.91 per share9.35QUREuniQure$27.12M29.13N/AN/A($0.14) per share-103.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADOCYAdocia-$10.09MN/A0.00∞N/AN/AN/AN/A9/25/2025 (Estimated)BPMUFBasilea Pharmaceutica$88.14MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)QUREuniQure-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)Latest ADOCY, OCS, BPMUF, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025QUREuniQure-$0.89N/AN/AN/AN/AN/A5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADOCYAdociaN/AN/AN/AN/AN/ABPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADOCYAdociaN/A1.081.07BPMUFBasilea Pharmaceutica1.184.854.16OCSOculisN/A4.794.79QUREuniQure1.5311.9911.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADOCYAdociaN/ABPMUFBasilea PharmaceuticaN/AOCSOculis22.30%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipADOCYAdociaN/ABPMUFBasilea PharmaceuticaN/AOCSOculisN/AQUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADOCYAdocia7818.28 millionN/ANot OptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableOCSOculis243.66 millionN/ANot OptionableQUREuniQure50054.78 million52.15 millionOptionableADOCY, OCS, BPMUF, and QURE HeadlinesRecent News About These CompaniesuniQure: Price And Value Have Caught UpJune 17, 2025 | seekingalpha.comuniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy OfficerJune 11, 2025 | globenewswire.comuniQure Provides Regulatory Update on AMT-130 for Huntington's DiseaseJune 2, 2025 | globenewswire.com3 Top Genomics Stocks to Add to Your Portfolio in 2025May 21, 2025 | zacks.comWall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?May 14, 2025 | zacks.comuniQure N.V. (QURE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comUniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2025 | zacks.comuniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company ProgressMay 9, 2025 | globenewswire.comuniQure to Announce First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comuniQure (QURE) Moves 38.5% Higher: Will This Strength Last?April 21, 2025 | zacks.comuniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A HoldApril 21, 2025 | seekingalpha.comuniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130April 21, 2025 | seekingalpha.comuniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's DiseaseApril 17, 2025 | globenewswire.comUniQure (QURE) Reports Q4 Loss, Misses Revenue EstimatesFebruary 27, 2025 | zacks.comuniQure Announces 2024 Financial Results and Highlights Recent Company ProgressFebruary 27, 2025 | globenewswire.comuniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsFebruary 7, 2025 | benzinga.comCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BFebruary 7, 2025 | prnewswire.comuniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseFebruary 3, 2025 | globenewswire.comuniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSJanuary 30, 2025 | globenewswire.comuniQure Announces Pricing of its Public OfferingJanuary 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADOCY, OCS, BPMUF, and QURE Company DescriptionsAdocia OTCMKTS:ADOCY$11.80 0.00 (0.00%) As of 07/15/2025Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.Basilea Pharmaceutica OTCMKTS:BPMUF$61.34 0.00 (0.00%) As of 07/15/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Oculis NASDAQ:OCS$17.86 -0.03 (-0.17%) Closing price 04:00 PM EasternExtended Trading$18.01 +0.15 (+0.83%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.uniQure NASDAQ:QURE$14.42 +0.46 (+3.30%) Closing price 04:00 PM EasternExtended Trading$14.43 +0.01 (+0.07%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
